β2-Glycoprotein I Autoantibodies

Eiji Matsuura, Luis R. Lopez

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Elevated serum levels of antiphospholipid antibodies, venous or arterial thrombosis, and/or pregnancy morbidity (miscarriages, recurrent fetal loss) are the major serologic and clinical features of the antiphospholipid syndrome (APS). Antiphospholipid antibodies belong to a heterogeneous family of autoantibodies that play a crucial role in the development of thrombosis in patients with APS. These antibodies may react with negatively charged phospholipids, phospholipid/protein complexes, and certain plasma proteins attached to suitable surfaces (i.e., activated cell membranes, oxygenated polystyrene). Most antiphospholipid antibodies derived from patients with APS require the presence of certain plasma proteins for optimal phospholipid binding activity. β2-Glycoprotein I (β2GPI), a phospholipid-binding plasma protein, is now recognized as the most clinically relevant antigenic target for antiphospholipid antibodies. Antibodies to β2GPI are more specific for thrombosis (and APS) than anticardiolipin (aCL) antibodies. Recent prospective studies have shown that β2GPI-dependent aCL and anti-γ2GPI antibodies were significant predictors of arterial thrombosis (myocardial infarction and stroke). In addition to natural anticoagulant properties, β2GPI may also bind to oxidized low-density lipoprotein (oxLDL) likely to quench its proinflammatory and atherogenic effects. Circulating oxLDL/β2GPI complexes are immunogenic, and anti-oxLDL/β2GPI antibodies accelerate their macrophage uptake and the development of autoimmune-mediated atherothrombosis. Autoantibodies against oxLDL/β2GPI complexes strongly correlated with arterial thrombosis in patients with systemic lupus erythematosus (SLE) and APS. These findings suggest that β2GPI and anti-γ2GPI antibodies play a central pathogenic role in thrombosis, and particularly in autoimmune-mediated atherosclerosis.

Original languageEnglish
Title of host publicationAutoantibodies: Third Edition
PublisherElsevier B.V.
Pages689-698
Number of pages10
ISBN (Print)9780444563781
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Autoantibodies
Glycoproteins
Antiphospholipid Syndrome
Antiphospholipid Antibodies
Thrombosis
Phospholipids
LDL Lipoproteins
Antibodies
Blood Proteins
Anticardiolipin Antibodies
Habitual Abortion
Polystyrenes
Systemic Lupus Erythematosus
Anticoagulants
Atherosclerosis
Carrier Proteins
Stroke
Macrophages
Myocardial Infarction
Cell Membrane

Keywords

  • Anti-beta2GPI antibodies
  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Atherosclerosis
  • Beta2-glycoprotein I
  • Inflammation
  • Thrombosis

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Matsuura, E., & Lopez, L. R. (2013). β2-Glycoprotein I Autoantibodies. In Autoantibodies: Third Edition (pp. 689-698). Elsevier B.V.. https://doi.org/10.1016/B978-0-444-56378-1.00081-2

β2-Glycoprotein I Autoantibodies. / Matsuura, Eiji; Lopez, Luis R.

Autoantibodies: Third Edition. Elsevier B.V., 2013. p. 689-698.

Research output: Chapter in Book/Report/Conference proceedingChapter

Matsuura, E & Lopez, LR 2013, β2-Glycoprotein I Autoantibodies. in Autoantibodies: Third Edition. Elsevier B.V., pp. 689-698. https://doi.org/10.1016/B978-0-444-56378-1.00081-2
Matsuura E, Lopez LR. β2-Glycoprotein I Autoantibodies. In Autoantibodies: Third Edition. Elsevier B.V. 2013. p. 689-698 https://doi.org/10.1016/B978-0-444-56378-1.00081-2
Matsuura, Eiji ; Lopez, Luis R. / β2-Glycoprotein I Autoantibodies. Autoantibodies: Third Edition. Elsevier B.V., 2013. pp. 689-698
@inbook{13c295928e76416e998703a7631ba769,
title = "β2-Glycoprotein I Autoantibodies",
abstract = "Elevated serum levels of antiphospholipid antibodies, venous or arterial thrombosis, and/or pregnancy morbidity (miscarriages, recurrent fetal loss) are the major serologic and clinical features of the antiphospholipid syndrome (APS). Antiphospholipid antibodies belong to a heterogeneous family of autoantibodies that play a crucial role in the development of thrombosis in patients with APS. These antibodies may react with negatively charged phospholipids, phospholipid/protein complexes, and certain plasma proteins attached to suitable surfaces (i.e., activated cell membranes, oxygenated polystyrene). Most antiphospholipid antibodies derived from patients with APS require the presence of certain plasma proteins for optimal phospholipid binding activity. β2-Glycoprotein I (β2GPI), a phospholipid-binding plasma protein, is now recognized as the most clinically relevant antigenic target for antiphospholipid antibodies. Antibodies to β2GPI are more specific for thrombosis (and APS) than anticardiolipin (aCL) antibodies. Recent prospective studies have shown that β2GPI-dependent aCL and anti-γ2GPI antibodies were significant predictors of arterial thrombosis (myocardial infarction and stroke). In addition to natural anticoagulant properties, β2GPI may also bind to oxidized low-density lipoprotein (oxLDL) likely to quench its proinflammatory and atherogenic effects. Circulating oxLDL/β2GPI complexes are immunogenic, and anti-oxLDL/β2GPI antibodies accelerate their macrophage uptake and the development of autoimmune-mediated atherothrombosis. Autoantibodies against oxLDL/β2GPI complexes strongly correlated with arterial thrombosis in patients with systemic lupus erythematosus (SLE) and APS. These findings suggest that β2GPI and anti-γ2GPI antibodies play a central pathogenic role in thrombosis, and particularly in autoimmune-mediated atherosclerosis.",
keywords = "Anti-beta2GPI antibodies, Antiphospholipid antibodies, Antiphospholipid syndrome, Atherosclerosis, Beta2-glycoprotein I, Inflammation, Thrombosis",
author = "Eiji Matsuura and Lopez, {Luis R.}",
year = "2013",
month = "12",
doi = "10.1016/B978-0-444-56378-1.00081-2",
language = "English",
isbn = "9780444563781",
pages = "689--698",
booktitle = "Autoantibodies: Third Edition",
publisher = "Elsevier B.V.",

}

TY - CHAP

T1 - β2-Glycoprotein I Autoantibodies

AU - Matsuura, Eiji

AU - Lopez, Luis R.

PY - 2013/12

Y1 - 2013/12

N2 - Elevated serum levels of antiphospholipid antibodies, venous or arterial thrombosis, and/or pregnancy morbidity (miscarriages, recurrent fetal loss) are the major serologic and clinical features of the antiphospholipid syndrome (APS). Antiphospholipid antibodies belong to a heterogeneous family of autoantibodies that play a crucial role in the development of thrombosis in patients with APS. These antibodies may react with negatively charged phospholipids, phospholipid/protein complexes, and certain plasma proteins attached to suitable surfaces (i.e., activated cell membranes, oxygenated polystyrene). Most antiphospholipid antibodies derived from patients with APS require the presence of certain plasma proteins for optimal phospholipid binding activity. β2-Glycoprotein I (β2GPI), a phospholipid-binding plasma protein, is now recognized as the most clinically relevant antigenic target for antiphospholipid antibodies. Antibodies to β2GPI are more specific for thrombosis (and APS) than anticardiolipin (aCL) antibodies. Recent prospective studies have shown that β2GPI-dependent aCL and anti-γ2GPI antibodies were significant predictors of arterial thrombosis (myocardial infarction and stroke). In addition to natural anticoagulant properties, β2GPI may also bind to oxidized low-density lipoprotein (oxLDL) likely to quench its proinflammatory and atherogenic effects. Circulating oxLDL/β2GPI complexes are immunogenic, and anti-oxLDL/β2GPI antibodies accelerate their macrophage uptake and the development of autoimmune-mediated atherothrombosis. Autoantibodies against oxLDL/β2GPI complexes strongly correlated with arterial thrombosis in patients with systemic lupus erythematosus (SLE) and APS. These findings suggest that β2GPI and anti-γ2GPI antibodies play a central pathogenic role in thrombosis, and particularly in autoimmune-mediated atherosclerosis.

AB - Elevated serum levels of antiphospholipid antibodies, venous or arterial thrombosis, and/or pregnancy morbidity (miscarriages, recurrent fetal loss) are the major serologic and clinical features of the antiphospholipid syndrome (APS). Antiphospholipid antibodies belong to a heterogeneous family of autoantibodies that play a crucial role in the development of thrombosis in patients with APS. These antibodies may react with negatively charged phospholipids, phospholipid/protein complexes, and certain plasma proteins attached to suitable surfaces (i.e., activated cell membranes, oxygenated polystyrene). Most antiphospholipid antibodies derived from patients with APS require the presence of certain plasma proteins for optimal phospholipid binding activity. β2-Glycoprotein I (β2GPI), a phospholipid-binding plasma protein, is now recognized as the most clinically relevant antigenic target for antiphospholipid antibodies. Antibodies to β2GPI are more specific for thrombosis (and APS) than anticardiolipin (aCL) antibodies. Recent prospective studies have shown that β2GPI-dependent aCL and anti-γ2GPI antibodies were significant predictors of arterial thrombosis (myocardial infarction and stroke). In addition to natural anticoagulant properties, β2GPI may also bind to oxidized low-density lipoprotein (oxLDL) likely to quench its proinflammatory and atherogenic effects. Circulating oxLDL/β2GPI complexes are immunogenic, and anti-oxLDL/β2GPI antibodies accelerate their macrophage uptake and the development of autoimmune-mediated atherothrombosis. Autoantibodies against oxLDL/β2GPI complexes strongly correlated with arterial thrombosis in patients with systemic lupus erythematosus (SLE) and APS. These findings suggest that β2GPI and anti-γ2GPI antibodies play a central pathogenic role in thrombosis, and particularly in autoimmune-mediated atherosclerosis.

KW - Anti-beta2GPI antibodies

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Atherosclerosis

KW - Beta2-glycoprotein I

KW - Inflammation

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84902070081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902070081&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-56378-1.00081-2

DO - 10.1016/B978-0-444-56378-1.00081-2

M3 - Chapter

SN - 9780444563781

SP - 689

EP - 698

BT - Autoantibodies: Third Edition

PB - Elsevier B.V.

ER -